Free Trial
NASDAQ:SLNO

Soleno Therapeutics Q2 2024 Earnings Report

Soleno Therapeutics logo
$73.30 -1.75 (-2.33%)
Closing price 04:00 PM Eastern
Extended Trading
$73.28 -0.02 (-0.02%)
As of 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Soleno Therapeutics EPS Results

Actual EPS
-$0.57
Consensus EPS
-$0.63
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Soleno Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Soleno Therapeutics Announcement Details

Quarter
Q2 2024
Time
After Market Closes
Conference Call Date
Wednesday, August 7, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Soleno Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Soleno Therapeutics Earnings Headlines

URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
Equities Analysts Issue Forecasts for SLNO FY2025 Earnings
See More Soleno Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Soleno Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Soleno Therapeutics and other key companies, straight to your email.

About Soleno Therapeutics

Soleno Therapeutics (NASDAQ:SLNO), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

View Soleno Therapeutics Profile

More Earnings Resources from MarketBeat